EXPERIENCE OF USING THE DRUG SELEXIPAG IN THE TREATMENT OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

被引：1
|
作者：
Karelkina, E. V. [1 ]
Goncharova, N. S. [1 ]
Simakova, M. A. [1 ]
Moiseeva, O. M. [1 ]
机构：
[1] FGBU Natl Med Res Ctr, St Petersburg, Russia
来源：
KARDIOLOGIYA | 2020年 / 60卷 / 04期
关键词：
PROSTACYCLIN-RECEPTOR AGONIST;
D O I：
10.18087/cardio.2020.4.n1026
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：36 / 42
页数：6
相关论文
共 50 条
  • [41] Selexipag in pulmonary arterial hypertension: a comprehensive review.
    Dakwa, David S.
    Mella, Lisa
    Mella, Natalie
    Poulakos, Mara N.
    PHARMACOTHERAPY, 2016, 36 (12): : E301 - E301
  • [42] Rosacea induced by selexipag in a patient with pulmonary arterial hypertension
    Dominguez-Santas, Miguel
    Diaz-Guimaraens, Borja
    Burgos-Blasco, Patricia
    Ortega-Quijano, Daniel
    Suarez-Valle, Ana
    Saceda-Corralo, David
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [43] Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series
    Fanous, Sherif M.
    Janmohamed, Munir
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (23) : 1877 - 1881
  • [44] Use of selexipag in a teenage patient with pulmonary arterial hypertension
    Bravo-Valenzuela, Nathalie Jeanne Magioli
    Navarro, Flavia
    Silva, Socrates Pereira
    ANNALS OF PEDIATRIC CARDIOLOGY, 2021, 14 (01) : 75 - 78
  • [45] Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
    Momoi, Mizuki
    Hiraide, Takahiro
    Shinya, Yoshiki
    Momota, Hiromi
    Fukui, Shogo
    Kawakami, Michiyuki
    Fukuda, Keiichi
    Kataoka, Masaharu
    RESPIRATORY MEDICINE CASE REPORTS, 2022, 36
  • [46] Three-A-Day Dosing of Selexipag in the Treatment of Pulmonary Arterial Hypertension: A Case Series
    Habib, N.
    Feldman, J. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [47] CLINICAL CHARACTERISTICS OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AND TREATMENT PATTERNS: A REAL-WORLD ANALYSIS FROM SPHERE (SELEXIPAG: THE USERS DRUG REGISTRY)
    McLaughlin, Vallerie
    Chin, Kelly
    Farber, Harrison
    Chakinala, Murali
    Highland, Kristin
    Hemnes, Anna
    Zhao, Carol
    Narayan, Veena
    Kim, Nick
    CHEST, 2021, 160 (04) : 2292A - 2295A
  • [48] Clinical Characteristics and Treatment Patterns in Patients with Pulmonary Arterial Hypertension (PAH) Initiating Selexipag in the EXPOSURE Observational Study
    Lange, T. J.
    Escribano, P.
    Biedermann, P.
    Muller, A.
    Sun, H.
    Soderberg, S.
    Gaine, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [49] Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension
    Ornstova, Eva
    Tuzil, Jan
    Chadimova, Katerina
    Mlcoch, Tomas
    Dolezal, Tomas
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (08) : 1269 - 1275
  • [50] Selexipag treatment in patients with systemic sclerosis-associated pulmonary arterial hypertension in clinical practice, a case series
    Lemmers, Jacqueline M. J.
    Fretheim, Havard
    Knaapen, Hanneke K. A.
    van den Hoogen, Frank H. J.
    Van Haren-Willems, Jolanda H. G. M.
    Duijnhouwer, Anthony L.
    van Dijk, Arie P.
    van den Ende, Cornelia H. M.
    Hoffmann-Vold, Anna-Maria
    Vonk, Madelon C.
    JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2020, 5 (03) : NP7 - NP11
12345